Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ocugen Inc
(NQ:
OCGN
)
1.330
+0.010 (+0.76%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ocugen Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema
February 27, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Present at Retinal Vascular Disease Drug Development Summit
February 17, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen to Host Conference Call on Tuesday, February 28 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2022 Financial Results
February 15, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen Appoints Quan A. Vu as Chief Business Officer
February 01, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference
January 31, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met
January 09, 2023
From
Ocugen
Via
GlobeNewswire
Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®
December 16, 2022
Important next step for Ocugen’s regenerative cell therapy in orthopedics since announcing pipeline expansion in May 2022
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. to Ring the Nasdaq Stock Market Closing Bell
December 13, 2022
From
Ocugen
Via
GlobeNewswire
Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis
December 07, 2022
From
Ocugen
Via
GlobeNewswire
Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit
November 28, 2022
From
Ocugen
Via
GlobeNewswire
Ocugen Provides Business Update & Third Quarter 2022 Financial Results
November 08, 2022
From
Ocugen
Via
GlobeNewswire
Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results
October 27, 2022
From
Ocugen
Via
GlobeNewswire
Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022
October 19, 2022
From
Ocugen
Via
GlobeNewswire
Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2
October 12, 2022
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences
October 06, 2022
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. to Present at Chardan’s 6th Annual Genetic Medicines Conference
September 29, 2022
From
Ocugen
Via
GlobeNewswire
Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan
September 28, 2022
From
Ocugen
Via
GlobeNewswire
MarketBeat: Week in Review 8/22 - 8/26
August 27, 2022
The markets are selling on news that interest rate hikes will continue past September. But here are some of the other stories for investors to follow this week
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Are Ocugen or Amarin Good Penny Stocks to Buy?
August 24, 2022
This article discusses the current state of Ocugen and Amarin, two penny stocks that highlight the risk and (potential) reward of penny stock investing.
Via
MarketBeat
OCUGEN INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Ocugen, Inc. - OCGN
October 08, 2021
From
Kahn Swick & Foti, LLC
Via
Business Wire
Ocugen, Inc. (NASDAQ:OCGN) Long Term Investor Alert: Investigation of Potential Wrongdoing
September 28, 2021
San Diego, CA -- (SBWIRE) -- 09/28/2021 -- Certain directors of Ocugen, Inc are under investigation concerning potential breaches of fiduciary duties by certain directors of Ocugen, Inc.
Via
SBWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
OCUGEN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Ocugen, Inc. - OCGN
September 10, 2021
From
Kahn Swick & Foti, LLC
Via
Business Wire
LAWSUITS FILED AGAINST OCGN, DKNG and PLL - Jakubowitz Law Pursues Shareholders Claims
August 17, 2021
NEW YORK, NY / ACCESSWIRE / August 17, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies...
From
Jakubowitz Law
Via
AccessWire
Topics
Fraud
Lawsuit
Exposures
Financial
Legal
Product Safety
CLASS ACTION UPDATE for OCGN, HMPT and ARDX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
August 16, 2021
NEW YORK, NY / ACCESSWIRE / August 16, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies....
From
Levi & Korsinsky, LLP
Via
AccessWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SRAC, OCGN and OTLY
August 16, 2021
NEW YORK, NY / ACCESSWIRE / August 16, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies....
From
The Gross Law Firm
Via
AccessWire
Exposures
Product Safety
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of OCGN, AHCO and ATVI
August 15, 2021
NEW YORK, NY / ACCESSWIRE / August 15, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies....
From
The Gross Law Firm
Via
AccessWire
Exposures
Product Safety
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Ocugen, Inc. and Encourages Investors to Contact the Firm
August 13, 2021
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
LAWSUITS FILED AGAINST OCGN, DKNG and BZ - Jakubowitz Law Pursues Shareholders Claims
August 13, 2021
NEW YORK, NY / ACCESSWIRE / August 13, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies...
From
Jakubowitz Law
Via
AccessWire
Topics
Fraud
Lawsuit
Exposures
Financial
Legal
Product Safety
CLASS ACTION UPDATE for OCGN, REKR and BLCT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
August 13, 2021
NEW YORK, NY / ACCESSWIRE / August 13, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies....
From
Levi & Korsinsky, LLP
Via
AccessWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ocugen, Inc. (OCGN)
August 13, 2021
From
The Law Offices of Frank R. Cruz
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.